Furthermore, by applying comprehensive genetic and histological analysis to the MRTX849-resistant tumor samples from 38 patients with NSCLC, CRC, and appendiceal cancer, Awad et al. released a list of alterations, including the oncogenic mutations of KRAS and other RAS proteins, KRAS G12C allele amplifications, loss-of-function mutations in genes regulating cell growth and division, and oncogenic fusions of RTKs to feed back RAS/MAPK pathway (29). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.